StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a research note issued to investors on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock.
A number of other research analysts also recently issued reports on the stock. Piper Sandler restated a "neutral" rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $106.08.
Check Out Our Latest Report on ITCI
Intra-Cellular Therapies Trading Up 0.0 %
Shares of ITCI traded up $0.04 during mid-day trading on Friday, hitting $131.85. 260,311 shares of the company traded hands, compared to its average volume of 1,387,373. The stock has a market capitalization of $14.04 billion, a price-to-earnings ratio of -151.54 and a beta of 0.69. The business has a 50-day moving average of $129.12 and a 200 day moving average of $99.80. Intra-Cellular Therapies has a one year low of $64.09 and a one year high of $131.87.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, analysts anticipate that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.
Institutional Trading of Intra-Cellular Therapies
Hedge funds have recently bought and sold shares of the stock. M&T Bank Corp increased its position in shares of Intra-Cellular Therapies by 2.2% during the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company's stock worth $526,000 after acquiring an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock worth $748,000 after purchasing an additional 141 shares during the period. CIBC Asset Management Inc increased its holdings in Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company's stock worth $247,000 after purchasing an additional 150 shares in the last quarter. Pallas Capital Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 6.4% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock valued at $266,000 after purchasing an additional 192 shares during the period. Finally, Arizona State Retirement System lifted its holdings in shares of Intra-Cellular Therapies by 0.8% in the fourth quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company's stock valued at $2,302,000 after purchasing an additional 206 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.
About Intra-Cellular Therapies
(
Get Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
